Pharmaceutical

Cellusion shares pipeline update for eye disease stem cell therapy

Cellusion shares Phase I/II clinical development plans for its bullous keratopathy stem cell therapy CSL-001.

Jun 29, 2023 - 20:00
Cellusion shares pipeline update for eye disease stem cell therapy
Cellusion shares Phase I/II clinical development plans for its bullous keratopathy stem cell therapy CSL-001.
Read the original article

Tags:

Previous Article

Pfizer’s Ngenla finally secures FDA approval following a rocky road to market

Next Article

The promising role of GLP-1RAs in NASH

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: More hospital and outpatient visits expected to persist through fall and winter

STAT+: More hospital and outpatient visits expected to ...

Oct 2, 2023

STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO

STAT+: BIO selects rare disease advocate, biotech execu...

Dec 5, 2023

STAT+: Boston Scientific’s drug-coated balloon may reduce risk of heart attack

STAT+: Boston Scientific’s drug-coated balloon may redu...

Oct 26, 2023